Other Blood and Immune Disorders in Chronic Kidney Disease

Comprehensive Clinical Nephrology: Fourth Edition

Volumn , Issue , 2010, Pages 959-968

  Hörl, Walter H ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882858980     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-05876-6.00080-0     Document Type: Chapter

References (31)

1. Hörl WH Thrombozytopathie und Blutungskomplikationen bei Urämie [Thrombocytopathy and blood complications in uremia]. Wien Klin Wochenschr 2006, 118:134-150.
2. Hedges SJ, Dehoney SB, Hooper JS, et al. Evidence-based treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol 2007, 3:138-153.
3. Ahmed I, Majeed A, Powell R Heparin induced thrombocytopenia: Diagnosis and management update. Postgrad Med J 2007, 83:575-582.
4. Reilly RF The pathophysiology of immune-mediated heparin-induced thrombocytopenia. Semin Dial 2003, 16:54-60.
5. Hutchinson CA, Dasgupta I National survey of hepatic-induced thrombocytopenia in the haemodialysis population of the UK population. Nephrol Dial Transplant 2007, 22:1680-1684.
6. Fischer KG Essentials of anticoagulation in hemodialysis. Hemodial Int 2007, 11:178-189.
7. Greinacher A, Warkentin TE The direct thrombin inhibitor hirudin. Thromb Haemost 2008, 99:819-829.
8. Link A, Girndt M, Selejan S, et al. Argatroban for anticoagulation in continuous renal replacement therapy. Crit Care Med 2009, 37:105-110.
9. Fox KA, Bassand JP, Mehta SR, et al. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. Ann Intern Med 2007, 147:304-310.
10. Kaufman JS, O'Connor TZ, Zhang JH, et al. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 2003, 14:2313-2321.
11. Dember LM, Beck GJ, Allon M, et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: A randomized controlled trial. JAMA 2008, 299:2164-2171.
12. Keltai M, Tonelli M, Mann JF, et al. Renal function and outcomes in acute coronary syndrome: Impact of clopidogrel. Eur J Cardiovasc Prev Rehabil 2007, 14:312-318.
13. Best PJ, Steinhubl SR, Berger PB, et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 2008, 155:687-693.
14. Dasgupta A, Steinhubl SR, Bhatt DL, et al. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). Am J Cardiol 2009, 103:1359-1363.
15. Krueger T, Westenfeld R, Ketteler M, et al. Vitamin K deficiency in CKD patients: A modifiable risk factor for vascular calcification?. Kidney Int 2009, 76:18-22.
16. Limdi NA, Beasley TM, Baird MF, et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 2009, 20:912-921.
17. Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009, 20:705-711.
18. Aronow WS Acute and chronic management of atrial fibrillation in patients with late-stage CKD. Am J Kidney Dis 2009, 53:701-710.
19. Cohen G, Hörl WH. Immune dysfunction in uremia: An update [invited review]. Blood Purif. in press.
20. Eleftheriadis T, Antoniadi G, Liakopoulos V, et al. Disturbances of acquired immunity in hemodialysis patients. Semin Dial 2007, 20:440-451.
21. Lim WH, Kireta S, Russ GR, et al. Uremia impairs blood dendritic cell function in hemodialysis patients. Kidney Int 2007, 71:1122-1131.
22. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311:1770-1773.
23. James MT, Laupland KB, Tonelli M, et al. Risk of bloodstream infection in patients with chronic kidney disease not treated with dialysis. Arch Intern Med 2008, 168:2333-2339.
24. Kong NC, Beran J, Kee SA, et al. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int 2008, 73:856-862.
25. Barraclough KA, Wiggins KJ, Hawley CM, et al. Intradermal versus intramuscular hepatitis B vaccination in hemodialysis patients: A prospective open-label randomized controlled trial in nonresponders to primary vaccination. Am J Kidney Dis 2009, 54:95-103.
26. Cruciani M, Mengoli C, Serpelloni G, et al. Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination: A meta-analysis. Vaccine 2007, 25:709-718.
27. Tanzi E, Amendola A, Pariani E, et al. Lack of effect of a booster dose of influenza vaccine in hemodialysis patients. J Med Virol 2007, 79:1176-1179.
28. Scharpé J, Peetermans WE, Vanwalleghem J, et al. Immunogenicity of a standard trivalent influenza vaccine in patients on long-term hemodialysis: An open-label trial. Am J Kidney Dis 2009, 54:77-85.
29. Pourfarziani V, Ramezani MB, Taheri S, et al. Immunogenicity of pneumococcal vaccination in renal transplant recipients and hemodialysis patients: A comparative controlled trial. Ann Transplant 2008, 13:43-47.
30. Vieira S, Baldacci ER, Carneiro-Sampaio M, et al. Evaluation of antibody response to the heptavalent pneumococcal conjugate vaccine in pediatric chronic kidney disease. Pediatr Nephrol 2009, 24:83-89.
31. Dinits-Pensy M, Forrest GN, Cross AS, et al. The use of vaccines in adult patients with renal disease. Am J Kidney Dis 2005, 46:997-1011.